Data from all patients in the study showed a median response duration of more than 45 weeks. Furthermore, analysis of the time to response showed that 85% of the responding patients obtained clinical response within eight weeks.
Additionally, previously released data was analyzed to assess the relation between dose and the serum concentration of HuMax-CD4 (zanolimumab) measured immediately before the next treatment (trough values). Increasing doses of HuMax-CD4 resulted in increased trough values. Furthermore, a 55% response rate was achieved in patients reaching lesser than or equal to 10mu g/ml serum concentration compared to only 6% in patients not reaching this serum level.
“This latest set of duration of response data is very encouraging and indicates that HuMax-CD4 may be effective in treating cutaneous T-cell lymphoma (CTCL) patients with mycosis fungoides, especially at higher doses,” said Dr Lisa Drakeman, CEO of Genmab.